Pathway-Level Metabolic Research : Examining how AOD 9604 affects pathways linked to fat and energy regulation, like -adrenergic and AMPK pathways, to understand how this peptide influences energy use in cells
The compound failed its Phase IIb obesity endpoint in 2007, and Metabolic Pharmaceuticals terminated clinical development the same year
Copper peptide targeting dermal papilla cell activity AHK-Cu is a copper peptide investigated for its effects on dermal papilla cell proliferation and vascular endothelial growth factor (VEGF) expression in scalp and skin tissue
By providing third-party verified, 99% pure NNMT inhibitors in protected lyophilized 5mg and 50mg vials, it delivers the consistency researchers need to study NAD+ enhancement, fat oxidation, and insulin sensitivity
It supports cellular repair, enhances digestive and barrier functions of the small intestine, modulates immune cell activity, and improves chromatin structure in aging cells, making it a promising research compound in aging biology and tissue regeneration 1-6 .
